SARS-CoV-2 (COVID-19) Full-Length Kappa Variant (B.1.617.1, India) Spike Recombinant Protein | 21-823

SARS-CoV-2 (COVID-19) Full-Length Kappa Variant (B.1.617.1, India) Spike Recombinant Protein | 21-823 | Gentaur UK, US & Europe Distribution

Tested Application: E

Application: This recombinant protein can be used for ELISA assays, Ligand binding assays (e.g. SPR), Biochemical and biophysical analyses. For research use only.

Tpredicted Molecular Weight: 1286 amino acids (including Rho1D4 tag and linker); 142115.37 Da

Physical State: Liquid

Buffer: 20 mM Hepes pH 7.5; 150 mM NaCl, 0.001 % LMNG

Storage Condition: –80˚C. Avoid freeze-thaw cycles

Alternate Name: SARS-CoV-2 (COVID-19) Spike Recombinant Protein: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Surface Glycoprotein, Spike protein

Background: N/A

Shipping: Dry Ice

Disclaimer: Products are intended for laboratory research purposes only and should be used by qualified personnel only. They are not intended for use in humans. ProSci is not liable for damages or injuries resulting from receipt and/or use of ProSci materials. Please refer to the Material Safety Data Sheet (MSDS) for safe storage, handling, and use procedures.

Source: HEK293 cells

Species: SARS-CoV-2 (COVID-19, 2019-nCoV) Spike Protein

By Source: Human Cells

By Species: Other

Fusion Tag: C-terminal Rho1D4

Sequence: Full-length sequence (aa 1 – 1273), G142D; E154K; L452R; E484Q
D614G; P681R; Q1071H
furin cleavage site “RRAR” mutated to “GSAG”; K986P; V987P
C-terminal Rho1D4 tag fused with spacer “GSSG” to protein sequence

Bological Activity: not determined

Purity: >98% as determined by SDS-PAGE, see Fig. 1 A and B. PureCube Rho1D4 Agarose.